NEW YORK, January 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. ( Nachrichten ) announced today that, through a wholly-owned subsidiary, it has signed an agreement with DOV Pharmaceutical, Inc. (PS: DOVP.PK) to in-license the worldwide rights for Bicifadine, a serotonin and norepinephrine reuptake inhibitor (SNRI).
From: www.finanznachrichten.de
XTL Biopharmaceuticals Announces the In-Licensing of Bicifadine - A Late-Stage Clinical Compound for the Treatment of ...
Posted by Ruslan Abuzant at 2:36 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment